|

ABT-301 Clinical Trials

1 actively recruiting trial

Also known as: Imofinostat, MPT0E028

Pipeline

Phase 1/2: 1

Top Sponsors

  • Anbogen Therapeutics, Inc.1

Indications

  • Colorectal Cancer (Diagnosis)1
  • Immunotherapy1
  • Colorectal Cancer Metastatic1
  • Colorectal Cancer (CRC)1
  • Cancer1

Other1 trial

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.